Rallybio Corporation (NASDAQ:RLYB) Short Interest Update

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 141,643 shares, a growth of 21.5% from the January 15th total of 116,605 shares. Currently, 3.0% of the company’s stock are short sold. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.0% of the company’s stock are short sold.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP lifted its position in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the last quarter. Geode Capital Management LLC raised its stake in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares in the last quarter. Citadel Advisors LLC lifted its position in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $40.00.

Rallybio Trading Up 1.0%

Shares of RLYB stock opened at $4.82 on Tuesday. The company has a market cap of $25.45 million, a P/E ratio of -1.88 and a beta of -1.05. The firm has a fifty day moving average price of $5.45 and a 200 day moving average price of $4.99. Rallybio has a 12 month low of $1.76 and a 12 month high of $6.75.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.